9PT Stock Overview
A clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Pliant Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.00 |
| 52 Week High | US$33.00 |
| 52 Week Low | US$3.98 |
| Beta | 1.38 |
| 11 Month Change | 0% |
| 3 Month Change | -0.62% |
| 1 Year Change | 420.33% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 48.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9PT | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | 0.2% |
| 1Y | 420.3% | -19.3% | 8.5% |
Return vs Industry: 9PT exceeded the German Pharmaceuticals industry which returned -28.7% over the past year.
Return vs Market: 9PT exceeded the German Market which returned 6.3% over the past year.
Price Volatility
| 9PT volatility | |
|---|---|
| 9PT Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 9PT's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 9PT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 124 | Bernard Coulie | pliantrx.com |
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company’s lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies.
Pliant Therapeutics, Inc. Fundamentals Summary
| 9PT fundamental statistics | |
|---|---|
| Market cap | €1.52b |
| Earnings (TTM) | -€111.91m |
| Revenue (TTM) | €8.79m |
172.6x
P/S Ratio-13.6x
P/E RatioIs 9PT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9PT income statement (TTM) | |
|---|---|
| Revenue | US$9.69m |
| Cost of Revenue | US$0 |
| Gross Profit | US$9.69m |
| Other Expenses | US$133.01m |
| Earnings | -US$123.32m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,273.32% |
| Debt/Equity Ratio | 3.2% |
How did 9PT perform over the long term?
See historical performance and comparison